Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.5.1.61 (
porphobilinogen deaminase
)
637
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We have monitored, during the dimethyl sulfoxide (Me2SO)-induced differentiation of MEL cells, the accumulation of mRNAs encoding two enzymes of the heme biosynthetic pathway, namely
porphobilinogen deaminase
and uroporphyrinogen decarboxylase. Our results demonstrate that the induction of these two enzymes is accounted for by a coordinate increase in their corresponding mRNAs, as estimated by hybridization with specific cloned cDNA probes. These events occur early during the differentiation process and precede the accumulation of alpha- and beta-globin mRNAs.
Blocking
the heme biosynthetic pathway with succinylacetone does not appear to modify the Me2SO-mediated increase of
porphobilinogen deaminase
and uroporphyrinogen decarboxylase mRNAs although succinylacetone has been shown to prevent the induction of immunoreactive
porphobilinogen deaminase
as well as its enzymatic activity (Beaumont, C., Deybach, J. C., Grandchamp, B., Da Silva, V., de Verneuil, H., and Nordmann, Y. (1984) Exp. Cell Res. 154, 474-484). Heme depletion resulting from the presence of succinylacetone in the culture medium reduces the extent of the Me2SO-mediated accumulation of alpha- and beta-globin mRNAs, and this effect is reversed by the addition of 10 microM exogenous hemin. Although the presence of succinylacetone prevents hemoglobinization of MEL cells, it does not prevent MEL cells from losing their proliferative capacity when treated with Me2SO.
...
PMID:Accumulation of porphobilinogen deaminase, uroporphyrinogen decarboxylase, and alpha- and beta-globin mRNAs during differentiation of mouse erythroleukemic cells. Effects of succinylacetone. 386 May 3
